| CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ... Alzheimer's & dementia 14 (11), 1470-1481, 2018 | 546 | 2018 |
| Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid T Bittner, H Zetterberg, CE Teunissen, RE Ostlund Jr, M Militello, ... Alzheimer's & dementia 12 (5), 517-526, 2016 | 301 | 2016 |
| ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease JL Cummings, S Cohen, CH van Dyck, M Brody, C Curtis, W Cho, M Ward, ... Neurology 90 (21), e1889-e1897, 2018 | 222 | 2018 |
| Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in … S Salloway, LA Honigberg, W Cho, M Ward, M Friesenhahn, F Brunstein, ... Alzheimer's research & therapy 10, 1-13, 2018 | 125 | 2018 |
| Upregulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer L Ryner, Y Guan, R Firestein, Y Xiao, Y Choi, C Rabe, S Lu, E Fuentes, ... Clinical cancer research 21 (13), 2941-2951, 2015 | 108 | 2015 |
| Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid T Yang, Y Dang, B Ostaszewski, D Mengel, V Steffen, C Rabe, T Bittner, ... Annals of neurology 86 (2), 215-224, 2019 | 81 | 2019 |
| Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials S Ostrowitzki, T Bittner, KM Sink, H Mackey, C Rabe, LS Honig, ... JAMA neurology 79 (11), 1113-1121, 2022 | 77 | 2022 |
| IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis J Wang, A Platt, R Upmanyu, S Germer, G Lei, C Rabe, R Benayed, ... BMJ open 3 (8), e003199, 2013 | 64 | 2013 |
| The alzheimer's disease prediction of longitudinal evolution (TADPOLE) challenge: Results after 1 year follow-up RV Marinescu, NP Oxtoby, AL Young, EE Bron, AW Toga, MW Weiner, ... arXiv preprint arXiv:2002.03419, 2020 | 50 | 2020 |
| Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening C Rabe, T Bittner, A Jethwa, I Suridjan, E Manuilova, M Friesenhahn, ... Alzheimer's & Dementia 19 (4), 1393-1402, 2023 | 21 | 2023 |
| Deep learning to predict geographic atrophy area and growth rate from multimodal imaging N Anegondi, SS Gao, V Steffen, RF Spaide, SVR Sadda, FG Holz, C Rabe, ... Ophthalmology Retina 7 (3), 243-252, 2023 | 21 | 2023 |
| Swedish Bio Fsg, Alzheimer’s Disease Neuroimaging Initiative (2018) CSF biomarkers of Alzheimer’s disease concord with amyloid-beta PET and predict clinical progression: A … O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ... Alzheimers Dement 14, 1470-1481, 0 | 18 | |
| Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications). C Bais, C Rabe, N Wild, M Swiatek-de Lange, D Chen, K Hong, L Amler, ... Journal of Clinical Oncology 32 (15_suppl), 3040-3040, 2014 | 17 | 2014 |
| Method comparison of AB (1-42) measured in human cerebrospinal fluid samples by liquid chromatography-tandem mass spectrometry, the INNO-BIA AlzBio3 assay, and the Elecsys® B … LM Shaw, L Fields, M Korecka, T Waligórska, JQ Trojanowski, ... Alzheimer's & Dementia 7 (12), P668, 2016 | 15 | 2016 |
| Blood-sampling collection prior to surgery may have a significant influence upon biomarker concentrations measured N Kahn, J Riedlinger, M Roeßler, C Rabe, M Lindner, I Koch, ... Clinical proteomics 12, 1-7, 2015 | 15 | 2015 |
| Alzheimer's Disease Neuroimaging Initiative CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated … O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ... Alzheimers Dement 14 (11), 1470-1481, 2018 | 11 | 2018 |
| STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF) J Swigris, S Nathan, R Tighe, S Nagra, C Rabe, D Kelkhoff, T Switzer, ... European Respiratory Journal 54 (suppl 63), 2019 | 10 | 2019 |
| A PAUC-based estimation technique for disease classification and biomarker selection M Schmid, T Hothorn, F Krause, C Rabe Statistical applications in genetics and molecular biology 11 (5), 2012 | 10 | 2012 |
| Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit SC Johnson, M Suárez-Calvet, I Suridjan, C Minguillón, JD Gispert, ... Alzheimer's Research & Therapy 15 (1), 25, 2023 | 6 | 2023 |
| DT‐01‐02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease P Scheltens, T Nikolcheva, R Lasser, S Ostrowitzki, M Boada, B Dubois, ... Alzheimer's & Dementia 11 (7S_Part_7), P331-P331, 2015 | 6 | 2015 |
